EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial

Michael Brunini, Jean-Marie Forel, Xavier Muracciole, Antoine Roch, Dominique Barbolosi, Laurent Papazian iD

Intensive Care Medicine · 2025

DOI: 10.1007/s00134-025-08064-z ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, 2025. Verfasst von Michael Brunini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Università di Corsica Pasquale Paoli, Corte, Corsica, France. Hauptthemen laut MEDLINE: Neuromuscular Blocking Agents, Atracurium, Respiratory Distress Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The beneficial effects of systematic cisatracurium administration observed in the ACURASYS randomized, multicenter, double-blinded trial may depend on patient-specific factors. This post hoc analysis aimed to explore whether the impact of cisatracurium on mortality varies with baseline characteristics. METHODS: A Markov chain analysis was conducted using daily clinical states from inclusion to day 90: death (state 0), under mechanical ventilation (state 1), or weaned and alive at day 90 (state 2). Patient trajectories were modeled accordingly. RESULTS: Among the 321 included patients, subgroup analysis following univariate analysis focused on 130 individuals under 60 years with non-fatal McCabe scores. Within this subgroup, cisatracurium administration and absence of vasopressor use significantly reduced the probability of remaining ventilated. Estimated survival increased therefore from 0.63 (placebo group, N = 62) to 0.93 (cisatracurium group, N = 68). In contrast, among patients with a rapidly or ultimately fatal prognosis according to McCabe score, the probability of survival did not differ substantially between the placebo and cisatracurium groups. Among patients with a PaO2:FiO2 ratio ≤ 100 mmHg at inclusion (N = 65), the estimated survival rate at day 90 was 0.93 in the cisatracurium arm compared with 0.63 in the placebo arm. For patients with a PaO2:FiO2 ratio > 100 mmHg at inclusion (N = 98), the corresponding survival rates were 0.92 and 0.63, respectively. In patients aged ≥ 60 years (N = 158), the daily probability of remaining mechanically ventilated was not influenced by any covariate, including the administration of cisatracurium. These results were confirmed by the performed simulations. CONCLUSION: The systematic and short-term administration of cisatracurium in patients with moderate-to-severe ARDS appears to confer greater survival benefit in those with a higher baseline life expectancy. Further validation through retrospective and prospective studies is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromuscular Blocking AgentsAtracuriumRespiratory Distress SyndromeHumansMarkov ChainsMiddle AgedMaleFemaleAgedDouble-Blind MethodRespiration, ArtificialAdultTreatment Outcome

Stichwörter der Autor:innen

Acute respiratory distress syndrome (ARDS)CisatracuriumMarkov chain analysisMechanical ventilationMortality predictors

Substanzen

Neuromuscular Blocking AgentsAtracuriumcisatracurium

Autor:innen und Institutionen

  • Università di Corsica Pasquale Paoli, Corte, Corsica, France.
  • Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, Marseille, France.
  • Aix-Marseille Université, Faculté des Sciences Médicales et Paramédicales, Centre d'Etudes et de Recherches sur les Services de Santé et Qualité de vie EA 3279, Marseille, France.
  • Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Département Oncologie-Radiothérapie, Aix-Marseille Université, Équipe Inria-Inserm COMPO, Pharmacologie Computationnelle et Oncologie Clinique, Centre Inria Sophi…
  • Aix-Marseille Université, Faculté de Pharmacie, Équipe Inria-Inserm COMPO, Pharmacologie Computationnelle et Oncologie Clinique, Centre Inria Sophia Antipolis-Méditerranée, Centre de Recherches en Cancérologie de Marsei…
  • Centre Hospitalier de Bastia, Médecine Intensive Réanimation, Chemin de Falconaja, Bastia, Corsica, France. laurent.papazian.pro@gmail.com.

ORCID-Profile: Laurent Papazian

Zitieren

APA

Brunini, M., Forel, J. M., Muracciole, X., Roch, A., Barbolosi, D., & Papazian, L. (2025). Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-025-08064-z

Vancouver

Brunini M, Forel JM, Muracciole X, Roch A, Barbolosi D, Papazian L. Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial. Intensive Care Medicine. 2025. doi:10.1007/s00134-025-08064-z

BibTeX
@article{Brunini2025,
  author = {Brunini, Michael and Forel, Jean-Marie and Muracciole, Xavier and Roch, Antoine and Barbolosi, Dominique and Papazian, Laurent},
  title = {Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial},
  journal = {Intensive Care Medicine},
  year = {2025},
  doi = {10.1007/s00134-025-08064-z}
}
Kostenlos starten →